EP2621931A4 - Dérivés d'indoles tétracycliques pour le traitement d'une infection par le virus de l'hépatite c - Google Patents
Dérivés d'indoles tétracycliques pour le traitement d'une infection par le virus de l'hépatite cInfo
- Publication number
- EP2621931A4 EP2621931A4 EP11827912.4A EP11827912A EP2621931A4 EP 2621931 A4 EP2621931 A4 EP 2621931A4 EP 11827912 A EP11827912 A EP 11827912A EP 2621931 A4 EP2621931 A4 EP 2621931A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- virus infection
- indole derivatives
- treating hepatitis
- tetracyclic indole
- tetracyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2010/077493 WO2012040923A1 (fr) | 2010-09-29 | 2010-09-29 | Dérivés d'indoles tétracycliques et leurs méthodes d'utilisation pour le traitement de maladies virales |
US201061426724P | 2010-12-23 | 2010-12-23 | |
PCT/CN2011/001638 WO2012041014A1 (fr) | 2010-09-29 | 2011-09-28 | Dérivés d'indoles tétracycliques pour le traitement d'une infection par le virus de l'hépatite c |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2621931A1 EP2621931A1 (fr) | 2013-08-07 |
EP2621931A4 true EP2621931A4 (fr) | 2014-03-19 |
Family
ID=45891857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11827912.4A Withdrawn EP2621931A4 (fr) | 2010-09-29 | 2011-09-28 | Dérivés d'indoles tétracycliques pour le traitement d'une infection par le virus de l'hépatite c |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2621931A4 (fr) |
JP (1) | JP2013538831A (fr) |
KR (1) | KR20140001879A (fr) |
AU (1) | AU2011307953B2 (fr) |
BR (1) | BR112013007696A2 (fr) |
CA (1) | CA2811662A1 (fr) |
MX (1) | MX2013003631A (fr) |
WO (1) | WO2012041014A1 (fr) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190127365A1 (en) | 2017-11-01 | 2019-05-02 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus replication |
TWI689305B (zh) | 2009-05-13 | 2020-04-01 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物 |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
NZ591973A (en) | 2009-06-11 | 2013-03-28 | Abbott Lab | Anti-viral compounds to treat hcv infection |
US8354419B2 (en) | 2009-07-16 | 2013-01-15 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
EP2550267A1 (fr) | 2010-03-24 | 2013-01-30 | Vertex Pharmaceuticals Incorporated | Analogues pour traiter ou prévenir les infections à flavivirus |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
CA2809261A1 (fr) | 2010-08-26 | 2012-03-01 | Rfs Pharma, Llc | Inhibiteurs puissants et selectifs du virus de l'hepatite c |
US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
BR112014000563A2 (pt) | 2011-07-09 | 2019-12-10 | Sunshine Lake Pharma Co., Ltd | composto, composição farmacêutica, e, uso do composto |
WO2013030750A1 (fr) | 2011-09-01 | 2013-03-07 | Lupin Limited | Composés antiviraux |
CN106166160A (zh) | 2011-09-16 | 2016-11-30 | 吉利德制药有限责任公司 | 用于治疗hcv的组合物 |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9073943B2 (en) | 2012-02-10 | 2015-07-07 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
TWI610916B (zh) | 2012-08-03 | 2018-01-11 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用 |
US9802949B2 (en) | 2012-11-29 | 2017-10-31 | Sunshine Lake Pharma Co., Ltd. | Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof |
CN103848821B (zh) | 2012-11-29 | 2016-10-12 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们的用途 |
WO2014110688A1 (fr) * | 2013-01-16 | 2014-07-24 | Merck Sharp & Dohme Corp. | Composés tétracycliques à substitution thiophène et leurs procédés d'utilisation pour le traitement des maladies virales |
WO2014110687A1 (fr) * | 2013-01-16 | 2014-07-24 | Merck Sharp & Dohme Corp. | Composés tétracycliques substitués par thiazolyle et leurs procédés d'utilisation pour le traitement de maladies virales |
US20140212491A1 (en) | 2013-01-31 | 2014-07-31 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
WO2014121417A1 (fr) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c |
WO2014121418A1 (fr) * | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Composés hétérocycliques tétracycliques et leurs méthodes d'utilisation pour le traitement de l'hépatite c |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
US9334291B2 (en) * | 2013-06-06 | 2016-05-10 | AB Pharma Ltd. | Antiviral compounds highly effective as HCV-NS5A inhibitor |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
JP2016527232A (ja) | 2013-07-17 | 2016-09-08 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Hcvの治療に使用するためのビフェニル誘導体を含む組み合わせ |
EP4005560A1 (fr) | 2013-08-27 | 2022-06-01 | Gilead Pharmasset LLC | Formulation de combinaison de deux composés antiviraux |
EP3063145A4 (fr) * | 2013-10-30 | 2017-08-23 | Merck Sharp & Dohme Corp. | Procédé de préparation de composés hétérocycliques tétracycliques |
WO2015089810A1 (fr) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Composés tétracycliques hétérocycliques condensés et leurs procédés d'utilisation pour le traitement de maladies virales |
WO2015103490A1 (fr) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Formes galéniques antivirales solides |
US9738629B2 (en) | 2014-01-23 | 2017-08-22 | Sunshine Lake Pharma Co., Ltd. | Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof |
WO2016004899A1 (fr) | 2014-07-11 | 2016-01-14 | Merck Sharp & Dohme Corp. | Procédé de préparation de composés hétérocycliques tétracycliques |
US10457690B2 (en) | 2015-06-04 | 2019-10-29 | Merck Sharp & Dohme Corp. | Process for preparing substituted tetracyclic heterocycle compounds |
US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN108290904B (zh) * | 2015-12-10 | 2020-10-09 | 正大天晴药业集团股份有限公司 | 氘修饰的elbasvir衍生物、含有该化合物的药物组合物及其用途 |
WO2017181947A1 (fr) * | 2016-04-20 | 2017-10-26 | 深圳市塔吉瑞生物医药有限公司 | Carbamate substitué de diamine, composition pharmaceutique et application correspondante |
WO2018032468A1 (fr) * | 2016-08-18 | 2018-02-22 | Merck Sharp & Dohme Corp. | Composés tétracycliques substitués par hétérocycles et leurs procédés d'utilisation pour le traitement de maladies virales |
WO2018032467A1 (fr) * | 2016-08-18 | 2018-02-22 | Merck Sharp & Dohme Corp. | Composés tétracycliques substitués par chromane et leurs utilisations dans le traitement de maladies virales |
RU2659388C1 (ru) | 2017-02-28 | 2018-07-02 | Васильевич Иващенко Александр | Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение |
RU2650610C1 (ru) | 2017-02-28 | 2018-04-16 | Васильевич Иващенко Александр | Противовирусная композиция и способ ее применения |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
US20080299075A1 (en) * | 2006-08-11 | 2008-12-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2010111483A1 (fr) * | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | Inhibiteurs de la réplication du virus de l'hépatite c |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2373172B1 (fr) * | 2008-12-03 | 2013-07-17 | Presidio Pharmaceuticals, Inc. | Inhibiteurs de la protéine ns5a du vhc |
KR20110098779A (ko) * | 2008-12-03 | 2011-09-01 | 프레시디오 파마슈티칼스, 인코포레이티드 | Hcv ns5a의 억제제 |
-
2011
- 2011-09-28 MX MX2013003631A patent/MX2013003631A/es not_active Application Discontinuation
- 2011-09-28 EP EP11827912.4A patent/EP2621931A4/fr not_active Withdrawn
- 2011-09-28 BR BR112013007696A patent/BR112013007696A2/pt not_active IP Right Cessation
- 2011-09-28 JP JP2013530529A patent/JP2013538831A/ja not_active Withdrawn
- 2011-09-28 WO PCT/CN2011/001638 patent/WO2012041014A1/fr active Application Filing
- 2011-09-28 AU AU2011307953A patent/AU2011307953B2/en not_active Expired - Fee Related
- 2011-09-28 CA CA2811662A patent/CA2811662A1/fr not_active Abandoned
- 2011-09-28 KR KR1020137010717A patent/KR20140001879A/ko not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
US20080299075A1 (en) * | 2006-08-11 | 2008-12-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2010111483A1 (fr) * | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | Inhibiteurs de la réplication du virus de l'hépatite c |
Non-Patent Citations (1)
Title |
---|
See also references of WO2012041014A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2013538831A (ja) | 2013-10-17 |
WO2012041014A1 (fr) | 2012-04-05 |
AU2011307953B2 (en) | 2014-07-31 |
EP2621931A1 (fr) | 2013-08-07 |
BR112013007696A2 (pt) | 2019-09-24 |
KR20140001879A (ko) | 2014-01-07 |
MX2013003631A (es) | 2013-10-01 |
AU2011307953A1 (en) | 2013-04-04 |
CA2811662A1 (fr) | 2012-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2621931A4 (fr) | Dérivés d'indoles tétracycliques pour le traitement d'une infection par le virus de l'hépatite c | |
EP2621932A4 (fr) | Composés hétérocycliques tétracycliques pour le traitement d'une infection par le virus de l'hépatite c | |
HUS1500019I1 (hu) | Hepatitisz C vírus inhibitorok | |
IL221033A0 (en) | Hepatitis c virus inhibitors | |
IL219516A0 (en) | Hepatitis c virus inhibitors | |
HK1163067A1 (en) | Hepatitis c virus inhibitors | |
IL219517A0 (en) | Hepatitis c virus inhibitors | |
EP2575819A4 (fr) | Inhibiteurs du virus de l'hépatite c | |
ZA201107095B (en) | Hepatitis c virus inhibitors | |
ZA201106795B (en) | Hepatitis c virus inhibitors | |
ZA201106669B (en) | Hepatitis c virus inhibitors | |
ZA201106629B (en) | Hepatitis c virus inhibitors | |
EP2512480A4 (fr) | Inhibiteurs du virus de l'hépatite c | |
EP2475256A4 (fr) | Inhibiteurs du virus de l'hépatite c | |
EP2491033A4 (fr) | Azaindazoles pour traiter une infection par le virus flaviviridae | |
HRP20171892T1 (hr) | Makrociklički derivati indola korisni kao inhibitori virusa hepatitisa c | |
EP2429568A4 (fr) | Composés macrocycliques comme inhibiteurs du virus de l'hépatite c | |
IL224298A (en) | Hepatitis virus inhibitors c | |
ZA201205547B (en) | Therapies for treating hepatitis c virus infection | |
EP2603080A4 (fr) | Inhibiteurs du virus de l'hépatite c | |
HK1208364A1 (en) | Method for treating hepatitis c virus infection using quercetin- containing compositions | |
EP2341924A4 (fr) | Méthodes de traitement d une infection par le virus de l hépatite c | |
ZA201300992B (en) | Combination therapy for treating hcv infection | |
PL2331554T3 (pl) | Makrocykliczne pochodne indolu użyteczne jako inhibitory wirusa zapalenia wątroby typu C | |
IL228725A0 (en) | Treatment of hepatitis c virus infection with alisporir |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130429 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20140213 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 31/12 20060101ALN20140207BHEP Ipc: C07D 487/04 20060101ALI20140207BHEP Ipc: C07D 471/04 20060101ALI20140207BHEP Ipc: C07D 498/04 20060101AFI20140207BHEP Ipc: A61K 31/5365 20060101ALI20140207BHEP Ipc: A61K 31/4985 20060101ALI20140207BHEP Ipc: A61K 31/437 20060101ALI20140207BHEP Ipc: A61P 31/14 20060101ALI20140207BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20150126 |